Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.

Cancer treatment reviews - 1 Dec 2017

Assis Joana, Pereira Carina, Nogueira Augusto, Pereira Deolinda, Carreira Rafael, Medeiros Rui

Abstract excerpt

BACKGROUND: The potential predictive value of genetic polymorphisms in ovarian cancer first-line treatment is inconsistently reported. We aimed to review ovarian cancer pharmacogenetic studies to update and summarize the available data and to provide directions for further research. METHODS: A systematic review followed by a meta-analysis was conducted on cohort studies assessing the involvement of genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutathione Transferase

Share to Models, Genetic

Share to Organoplatinum Compounds

Share to Ovarian Neoplasms

Share to Taxoids

Share to Treatment Outcome

Source

Identifiers

PMID: 29100168
DOI: 10.1016/j.ctrv.2017.10.001

Genes

GSTM1
ERCC1
ERCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.PMID 29100168Read ↗

Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.Semantic proximity Read ↗

Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.Semantic proximity Read ↗

Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.Semantic proximity Read ↗

Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.Semantic proximity Read ↗

Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.Semantic proximity Read ↗

The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].Semantic proximity Read ↗

Multigene germline and somatic testing for epithelial ovarian cancer in ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.